Search research articles
Contact Us
Filters
Showing results (101-110 of 135) with videos related to
Page
of 14
Sort By:
Advances in Therapy
|
December 28, 2020
A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries
Alexander C J van Akkooi, Sebastian Haferkamp, Sophie Papa, et al.
Dermatology and Therapy
|
January 20, 2022
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
Jeffrey J Crowley, Richard G Langley, Kenneth B Gordon, et al.
BMJ Open
|
April 24, 2023
Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
Christian Boisvert-Huneault, David Trigos Herraez, Andreas Pinter, et al.
JAAD International
|
December 2, 2024
Efficacy and safety of guselkumab in European patients with palmoplantar pustulosis: A multi-center, single-arm clinical trial (GAP study)
Dagmar Wilsmann-Theis, Selina Patt, Andreas Pinter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 29, 2022
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)
Andreas Pinter, Luis Puig, Knut Schäkel, et al.
The Journal of Investigative Dermatology
|
December 4, 2018
Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks
Esther von Stebut, Kristian Reich, Diamant Thaçi, et al.
Lancet (London, England)
|
April 19, 2025
Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial
Ana Maria Giménez-Arnau, Andreas Pinter, Wiebke Sondermann, et al.
Journal of Drugs in Dermatology : JDD
|
August 2, 2024
Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas
Alice B Gottlieb, April Armstrong, Andrew Blauvelt, et al.
Annals of the Rheumatic Diseases
|
August 20, 2024
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
Laure Gossec, Laura C Coates, Dafna D Gladman, et al.
JAAD International
|
February 3, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)
Kristina Callis Duffin, Christopher E M Griffiths, Matthias Hoffmann, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 135) with videos related to
Sort By:
Page
of 14
Advances in Therapy
|
December 28, 2020
A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries
Alexander C J van Akkooi, Sebastian Haferkamp, Sophie Papa, et al.
Dermatology and Therapy
|
January 20, 2022
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
Jeffrey J Crowley, Richard G Langley, Kenneth B Gordon, et al.
BMJ Open
|
April 24, 2023
Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
Christian Boisvert-Huneault, David Trigos Herraez, Andreas Pinter, et al.
JAAD International
|
December 2, 2024
Efficacy and safety of guselkumab in European patients with palmoplantar pustulosis: A multi-center, single-arm clinical trial (GAP study)
Dagmar Wilsmann-Theis, Selina Patt, Andreas Pinter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 29, 2022
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)
Andreas Pinter, Luis Puig, Knut Schäkel, et al.
The Journal of Investigative Dermatology
|
December 4, 2018
Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks
Esther von Stebut, Kristian Reich, Diamant Thaçi, et al.
Lancet (London, England)
|
April 19, 2025
Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial
Ana Maria Giménez-Arnau, Andreas Pinter, Wiebke Sondermann, et al.
Journal of Drugs in Dermatology : JDD
|
August 2, 2024
Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas
Alice B Gottlieb, April Armstrong, Andrew Blauvelt, et al.
Annals of the Rheumatic Diseases
|
August 20, 2024
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
Laure Gossec, Laura C Coates, Dafna D Gladman, et al.
JAAD International
|
February 3, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)
Kristina Callis Duffin, Christopher E M Griffiths, Matthias Hoffmann, et al.
Page
of 14